Related Experiment Video
Updated: Jan 7, 2026

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
Published on: August 16, 2024
Extracellular vesicle-based therapies for neurodegenerative diseases
Guoku Hu1, Christina Gogzheyan1,2, Sudipta Panja1
1Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Extracellular vesicles (EVs) are implicated in neurodegenerative diseases but also show therapeutic potential. Colostrum-derived EVs offer a promising, natural source for neuroprotective treatments targeting brain disorders.
Area of Science:
- Neuroscience
- Biotechnology
- Cell Biology
Background:
- Extracellular vesicles (EVs) play a dual role in neurodegenerative diseases.
- EVs contribute to the spread of misfolded proteins like beta-amyloid and tau.
- They also promote neuroinflammation by activating glial cells.
Purpose of the Study:
- To explore the therapeutic potential of EVs for central nervous system disorders.
- To investigate EVs as drug delivery vehicles across the blood-brain barrier.
- To identify natural sources of EVs for neuroprotection.
Main Methods:
- Review of literature on EV function in neurodegeneration.
- Analysis of EV cargo (cytokines, RNAs, proteins).
- Evaluation of colostrum-derived EVs for therapeutic applications.
Main Results:
- EVs facilitate the propagation of neurotoxic proteins and neuroinflammation.
- EVs can be engineered for targeted drug delivery of neuroprotective agents.
- Colostrum-derived EVs are rich in growth factors and microRNAs, suggesting therapeutic value.
Conclusions:
- EVs exhibit 'Janus-faced' properties, acting as both disease mediators and therapeutic tools.
- Modulating EV activity presents a strategy for immune-based neurodegenerative disease therapeutics.
- Colostrum-derived EVs represent a scalable, biocompatible source for neuroprotection.
Related Concept Videos
Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Microorganisms in Medicine and Therapeutics
Fusion of Secretory Vesicles with the Plasma Membrane
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

